These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 34324792

  • 1. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
    Shiihara J, Ohyanagi F, Amari H, Toda M, Tahara H, Yuzawa M, Maeda Y, Nomura M, Mizushina Y, Nagai Y, Ohta H, Yamaguchi Y.
    Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
    [Abstract] [Full Text] [Related]

  • 2. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N, Nakashima K, Naito T, Nakajima T, Endo M, Takahashi T.
    BMC Cancer; 2017 Jul 06; 17(1):471. PubMed ID: 28683775
    [Abstract] [Full Text] [Related]

  • 3. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
    Tanaka H, Taima K, Morimoto T, Nakamura K, Tanaka Y, Itoga M, Takanashi S, Okumura K.
    BMC Res Notes; 2016 Mar 17; 9():173. PubMed ID: 26987388
    [Abstract] [Full Text] [Related]

  • 4. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z, Li P, Yan B, Gao Q, Jiang X, Zhan Z, Yan Q, Lizaso A, Huang C.
    Thorac Cancer; 2020 Jan 17; 11(1):176-180. PubMed ID: 31766077
    [Abstract] [Full Text] [Related]

  • 5. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M, An Z, Tang Q, Ma Y, Yan J, Chen S, Wang Y.
    J Cell Mol Med; 2021 Oct 17; 25(19):9476-9481. PubMed ID: 34541785
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K.
    Clin Lung Cancer; 2016 Nov 17; 17(6):528-534. PubMed ID: 27318655
    [Abstract] [Full Text] [Related]

  • 9. A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.
    Tamiya A, Shimizu S, Atagi S.
    J Thorac Oncol; 2015 Aug 17; 10(8):e74. PubMed ID: 26200283
    [No Abstract] [Full Text] [Related]

  • 10. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC, Liu YH, Ding KL, Liu YF, Zhao WJ, Zhu YJ, Chang XS, Chen YD, Xiao ZZ, Yu YY, Zhou R, Zhang HB.
    BMC Cancer; 2021 Nov 26; 21(1):1278. PubMed ID: 34836510
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q, Xu H, Liu Y, Zhang W, Sun C, Hu M, Zhu Y, Tan S, Xu X, Wang S, Liu L.
    Lung Cancer; 2021 Dec 26; 162():86-89. PubMed ID: 34763158
    [Abstract] [Full Text] [Related]

  • 13. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N, Fujita A, Saikai T, Takabatake H, Sotoshiro M, Sekine K, Kawana A.
    Intern Med; 2018 Mar 01; 57(5):713-716. PubMed ID: 29151522
    [Abstract] [Full Text] [Related]

  • 14. Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.
    Zhang Y, Qin Y, Xu H, Yao Q, Gao Y, Feng Y, Ren J.
    Pathol Oncol Res; 2021 Mar 01; 27():637745. PubMed ID: 34257603
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.
    Sun K, Nie L, Nong L, Cheng Y.
    Thorac Cancer; 2021 Jun 01; 12(12):1927-1930. PubMed ID: 33960639
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, Wei YF, Lee KY, Tseng YH, Su J, Chung HP, Lin CB, Ku WH, Chiang TS, Chiu CH, Shih JY.
    Eur J Cancer; 2021 Oct 01; 156():1-11. PubMed ID: 34392186
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.